https://pmc.ncbi.nlm.nih.gov/articles/PMC11507497/

After millennia of widespread clinical use and rigorous scientific scrutiny throughout the 20th century, therapeutic phlebotomy has not faded from modern medicine but undergone a remarkable renaissance anchored in evidence-based medicine. Evolving from indiscriminate empirical intervention to targeted precision treatment, modern phlebotomy has built robust clinical evidence across four core fields and become an irreplaceable physical therapeutic modality for selected diseases.

Cornerstone Role in Hematological Disorders

Polycythemia vera (PV) remains the quintessential modern indication for therapeutic phlebotomy. Per the WHO 2016 diagnostic criteria, venesection is designated first-line therapy for male patients with hemoglobin >185 g/L and female patients with hemoglobin >165 g/L. Guidelines issued by the European Hematology Association recommend an initial regimen of 250–500 mL phlebotomy every 2 to 4 days until hematocrit (HCT) drops below 45%, followed by maintenance venesection once every 3 to 4 months. The CYTO-PV trial published in the New England Journal of Medicine in 2019 demonstrated that patients with tightly controlled HCT ≤45% exhibited a fourfold reduction in cardiovascular events compared with the control cohort maintaining HCT between 45% and 50%.

Phlebotomy serves as a definitive causal treatment for hereditary hemochromatosis (HH). Pathogenic HFE gene mutations trigger excessive intestinal iron absorption, and regular blood removal stands as the only proven intervention to deplete excess systemic iron stores. Recommendations from the American Association for the Study of Liver Diseases specify initial weekly 500 mL phlebotomy (eliminating roughly 250 mg elemental iron per session) until serum ferritin falls below 50 ng/mL, followed by maintenance treatment every 3–4 months. A 2020 multicenter French clinical study verified that consistent phlebotomy yielded a 63% 10-year hepatic fibrosis regression rate and a 76% reduction in hepatocellular carcinoma risk among HH patients.

Adjunctive Therapy for Cardiovascular Diseases

For treatment-resistant hypertension, the ROX Coupler System received US FDA approval in 2018 to deliver targeted phlebotomy via carotid-jugular anastomosis, lowering systolic blood pressure by more than 25 mmHg. Its therapeutic mechanisms include: ① reducing circulating blood volume by 800–1200 mL; ② diminishing venous return to decrease cardiac preload; ③ modulating baroreceptor sensitivity. Eligibility is strictly restricted to patients refractory to triple-drug antihypertensive regimens, ineligible for renal artery ablation, and with estimated glomerular filtration rate >45 mL/min.

The emerging concept of controlled venous congestion has spawned innovative phlebotomy protocols for chronic heart failure. The CARDIOREDUCE research published in the Journal of the American College of Cardiology (2017) reported that monthly adjunctive 300 mL phlebotomy alongside diuretic therapy reduced BNP concentrations by 35% and extended six-minute walking distance by 42 meters in NYHA Class III heart failure patients. Central venous pressure (CVP) monitoring guides treatment to maintain post-procedure CVP within the optimal range of 6–8 mmHg.

Innovative Applications in Metabolic Disorders

Novel therapeutic approaches have emerged for non-alcoholic fatty liver disease (NAFLD). The 2021 HEMOFIB trial in Hepatology first confirmed that NAFLD patients with mild iron overload (serum ferritin >200 μg/L) receiving six cycles of 250 mL biweekly phlebotomy achieved a 5.2% decline in hepatic fat content (quantified via MRI-PDFF) and a 31% improvement in the homeostatic model assessment for insulin resistance (HOMA-IR). Beneficial pathways encompass: ① alleviating free iron-mediated oxidative stress; ② mitigating hepatocyte ferroptosis; ③ regulating the hepcidin-ferroportin signaling axis.

Breakthrough findings on inflammatory modulation via phlebotomy have advanced metabolic syndrome research. Researchers at the University of Tübingen, Germany, found that monthly 200 mL venesection downregulated monocytic TLR4 expression by 37% and reduced circulating TNF-α levels by 28%. Such controlled blood loss activates hypoxia-inducible factor HIF-2α and stimulates secretion of anti-inflammatory cytokine IL-10, generating exercise-mimicking systemic anti-inflammatory effects.

Expanded Indications in Special Clinical Settings

Preventive phlebotomy is formally incorporated into China's medical support guidelines for the Qinghai–Tibet Railway to manage high-altitude polycythemia. For individuals with hemoglobin >200 g/L and peripheral oxygen saturation <85%, 300 mL phlebotomy every three months cuts cerebral thrombosis incidence by 68%. Data from Canada's Arctic Medical Center shows regular phlebotomy among Inuit populations correlates with a 12 mmHg lower pulmonary artery systolic pressure versus untreated controls.

Sports medicine has pioneered the concept of physiological blood conditioning. A 2022 systematic review in Medicine & Science in Sports & Exercise concluded moderate phlebotomy (5 mL per kilogram body weight) during altitude training preserves plasma volume while boosting endogenous erythropoietin production, raising maximal oxygen uptake by 3.8% upon athletes' return to lowland environments. Concurrent iron supplementation is mandatory to prevent sports-induced anemia.

Precision Optimization Enabled by Technical Innovation

Modern phlebotomy equipment has evolved toward intelligent automation. Fresenius' automated apheresis devices isolate and remove red blood cells while autotransfusing residual plasma; each session eliminating 300 mL red cell volume (≈200 mg iron) takes only 35 minutes. Standards from the American Association of Blood Banks mandate continuous ambient temperature control at 22±2 °C, flow velocity capped below 100 mL/min, and real-time electrocardiographic surveillance throughout treatment.

Sophisticated monitoring protocols bolster procedural safety: non-invasive hemoglobin measurement using Masimo Rainbow technology delivers Hb readings every 20 seconds; bioimpedance-based body composition monitors track dynamic fluid shifts; thromboelastography (TEG) evaluates real-time coagulation function. These analytical tools transform phlebotomy from subjective empirical manipulation into data-driven personalized therapy.